Postmenopausal hormone therapy and Alzheimer's disease risk

Interaction with age

Victor W. Henderson, Kelly Benke, R. C. Green, L. A. Cupples, L. A. Farrer

Research output: Contribution to journalArticle

Abstract

We examined the relation between oestrogen containing hormone therapy (HT) used for more than 6 months and Alzheimer's disease (AD) risk in 971 postmenopausal women (426 AD patients, 545 relatives without dementia). There was a significant interaction between age and HT use on AD risk (p = 0.03). In stratified analyses, a significant protective association was seen only in the youngest age fertile (50-63 years; odds ratio = 0.35, 95% confidence interval = 0.19 to 0.66). Results must be considered cautiously in light of recent clinical trial evidence that oestrogen plus progestin increases dementia incidence in older post-menopausal women. However, our observational findings are consistent with the view that HT may protect younger women from AD or reduce the risk of early onset forms of AD, or that HT used during the early postmenopause may reduce AD risk.

Original languageEnglish (US)
Pages (from-to)103-105
Number of pages3
JournalJournal of Neurology Neurosurgery and Psychiatry
Volume76
Issue number1
DOIs
StatePublished - Jan 2005
Externally publishedYes

Fingerprint

Alzheimer Disease
Hormones
Dementia
Estrogens
Postmenopause
Therapeutics
Progestins
Odds Ratio
Clinical Trials
Confidence Intervals
Incidence

ASJC Scopus subject areas

  • Psychiatry and Mental health
  • Neuroscience(all)
  • Neuropsychology and Physiological Psychology

Cite this

Postmenopausal hormone therapy and Alzheimer's disease risk : Interaction with age. / Henderson, Victor W.; Benke, Kelly; Green, R. C.; Cupples, L. A.; Farrer, L. A.

In: Journal of Neurology Neurosurgery and Psychiatry, Vol. 76, No. 1, 01.2005, p. 103-105.

Research output: Contribution to journalArticle

Henderson, Victor W. ; Benke, Kelly ; Green, R. C. ; Cupples, L. A. ; Farrer, L. A. / Postmenopausal hormone therapy and Alzheimer's disease risk : Interaction with age. In: Journal of Neurology Neurosurgery and Psychiatry. 2005 ; Vol. 76, No. 1. pp. 103-105.
@article{95bc19aa7c4942f5be0e9b9a20c0c4dd,
title = "Postmenopausal hormone therapy and Alzheimer's disease risk: Interaction with age",
abstract = "We examined the relation between oestrogen containing hormone therapy (HT) used for more than 6 months and Alzheimer's disease (AD) risk in 971 postmenopausal women (426 AD patients, 545 relatives without dementia). There was a significant interaction between age and HT use on AD risk (p = 0.03). In stratified analyses, a significant protective association was seen only in the youngest age fertile (50-63 years; odds ratio = 0.35, 95{\%} confidence interval = 0.19 to 0.66). Results must be considered cautiously in light of recent clinical trial evidence that oestrogen plus progestin increases dementia incidence in older post-menopausal women. However, our observational findings are consistent with the view that HT may protect younger women from AD or reduce the risk of early onset forms of AD, or that HT used during the early postmenopause may reduce AD risk.",
author = "Henderson, {Victor W.} and Kelly Benke and Green, {R. C.} and Cupples, {L. A.} and Farrer, {L. A.}",
year = "2005",
month = "1",
doi = "10.1136/jnnp.2003.024927",
language = "English (US)",
volume = "76",
pages = "103--105",
journal = "Journal of Neurology, Neurosurgery and Psychiatry",
issn = "0022-3050",
publisher = "BMJ Publishing Group",
number = "1",

}

TY - JOUR

T1 - Postmenopausal hormone therapy and Alzheimer's disease risk

T2 - Interaction with age

AU - Henderson, Victor W.

AU - Benke, Kelly

AU - Green, R. C.

AU - Cupples, L. A.

AU - Farrer, L. A.

PY - 2005/1

Y1 - 2005/1

N2 - We examined the relation between oestrogen containing hormone therapy (HT) used for more than 6 months and Alzheimer's disease (AD) risk in 971 postmenopausal women (426 AD patients, 545 relatives without dementia). There was a significant interaction between age and HT use on AD risk (p = 0.03). In stratified analyses, a significant protective association was seen only in the youngest age fertile (50-63 years; odds ratio = 0.35, 95% confidence interval = 0.19 to 0.66). Results must be considered cautiously in light of recent clinical trial evidence that oestrogen plus progestin increases dementia incidence in older post-menopausal women. However, our observational findings are consistent with the view that HT may protect younger women from AD or reduce the risk of early onset forms of AD, or that HT used during the early postmenopause may reduce AD risk.

AB - We examined the relation between oestrogen containing hormone therapy (HT) used for more than 6 months and Alzheimer's disease (AD) risk in 971 postmenopausal women (426 AD patients, 545 relatives without dementia). There was a significant interaction between age and HT use on AD risk (p = 0.03). In stratified analyses, a significant protective association was seen only in the youngest age fertile (50-63 years; odds ratio = 0.35, 95% confidence interval = 0.19 to 0.66). Results must be considered cautiously in light of recent clinical trial evidence that oestrogen plus progestin increases dementia incidence in older post-menopausal women. However, our observational findings are consistent with the view that HT may protect younger women from AD or reduce the risk of early onset forms of AD, or that HT used during the early postmenopause may reduce AD risk.

UR - http://www.scopus.com/inward/record.url?scp=10944251718&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=10944251718&partnerID=8YFLogxK

U2 - 10.1136/jnnp.2003.024927

DO - 10.1136/jnnp.2003.024927

M3 - Article

VL - 76

SP - 103

EP - 105

JO - Journal of Neurology, Neurosurgery and Psychiatry

JF - Journal of Neurology, Neurosurgery and Psychiatry

SN - 0022-3050

IS - 1

ER -